Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. Its pipeline focuses on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's lead product candidate, EVO756, is an oral small molecule antagonist of MRGPRX2 currently in Phase 2 trials for urticaria and atopic dermatitis, with plans to evaluate it for migraine. Its second candidate, EVO301, is a long-acting fusion protein targeting IL-18, which has completed a Phase 2a trial in atopic dermatitis and is moving toward Phase 2b development. Evommune targets key drivers of inflammation and neuroimmune interactions in these conditions.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage ir.evommune.com
Sector Healthcare IR page ir.evommune.com
Tags
chronic inflammatory diseases, atopic dermatitis, chronic spontaneous urticaria, ulcerative colitis, small molecule drugs, fusion proteins, immunology, mast cell biology, neuroinflammation, il-18 pathway, EVO756, EVO301
Press page —

Metrics

Valuation  
Market cap $ 300.523M
Market cap (USD) $ 300.523M
P/E -0.74
PEG —
P/BV 1.20
P/S 23.12
P/OCF -3.93
P/FCF -3.92
Dividend yield —
Turnover / mcap —
Returns  
ROE -33.5%
ROI -42.6%
ROIC -37.6%
Profit margin -529.8%
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 10
Quality score -63.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024
Revenue 13M 0
Net profit -68.87M —
Free cash flow -76.676M —

Figure FY 2025 FY 2024
Share price 17.12 —
P/FCF -7.04 —

Filed figures

Figure Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 487,000 2.06M
Cash and deposits (USD) 29.2M 16.3M 44.1M
Right-of-use assets (USD) — 472,000 1.47M
Cash flow detail
Operating cash flow (USD) — -58.2M -76.4M
Purchases of property, plant and equipment (USD) — -88,000 -235,000
Change in payables (cash effect) (USD) — 6.51M -837,000
Interest paid (cash effect) (USD) — -34,000 -7,000
Share-based compensation (USD) — 1.72M 5.86M
Free cash flow (OCF - PPE - intangibles) (USD) — -58.3M -76.7M
Income detail
Research and development expense (USD) — 64.2M 74M
Reported Dec 11, 2025 Mar 5, 2026 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Retention Awards On November 13, 2026, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Evommune, Inc. (the “Company”) approved the entry of an amendment to the applicable employment agreement(s) (each an “Amendment”) with certain executive officers of the Company, including the Chief Executive Officer, the Chief Financial Officer, and the Chief Business & Legal Officer, pursuant to which, effective upon the execution of the Amendment by each officer (each, an “Amendment Effective Date”), such officer will be eligible to earn a cash retention award (each a “Retention Award”). The amounts of such Retention Awards for the Chief Executive Officer, the Chief Financial Officer, and the Chief Business & Legal Officer are set forth below:

Luis Peña, President and Chief Executive Officer $686,600

Kyle Carver, Chief Financial Officer $565,000

Gregory Moss, Chief Business & Legal Officer $595,000

The Retention Awards, less any necessary deductions, will be payable by the Company in two equal installments subject to vesting.

Expanded pipeline with in-licensing of EVO570, a potential best-in-class oral VAV-1 molecular glue degrader

EVO301 late-breaking EADV data demonstrate clear therapeutic signal and favorable safety and tolerability profile, supporting Phase 2b trial in AD expected for mid-2027 initiation

Additional clinical milestones expected in 2027, including initiation of the EVO570 Phase 1 trial in early 2027, the EVO301 Phase 2 trial in ulcerative colitis and the EVO646 Phase 1 study

Key 2027 data expected to include Phase 1 healthy volunteer and biomarker data for EVO570 and EVO646, and top-line Phase 2b migraine data for EVO756

Strong balance sheet with cash runway into 2H 2029 to deliver multiple key milestones across the pipeline

PALO ALTO, Calif. & NEW YORK, November 12, 2026 - Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

Management to discuss the in-licensing of EVO570, an oral VAV1-directed molecular glue degrader

PALO ALTO, Calif., NEW YORK, November 5, 2026 – Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that a pre-recorded webcast will be available at 8:30 a.m. E.T. today.

On the webcast, President and Chief Executive Officer Luis Peña and members of the management team will discuss EVO570, a potential best-in-class oral VAV1-directed molecular glue degrader. Evommune previously announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals Inc. (SSE: 688302) granting Evommune worldwide rights outside of Greater China to develop, manufacture and commercialize EVO570 (formerly HC118 and known as HP570 in Greater China), an oral VAV1-directed molecular glue degrader (MGD). Management will cover the biology of VAV1, EVO570’s preclinical profile, the planned development path in rheumatoid arthritis, the terms of the transaction and how EVO570 fits within the Company’s broader immunology pipeline.

Prompts

Evommune, Inc. (ticker EVMN), listed in United States.

ETFs Holding Evommune, Inc.

ETF Weight in ETF Shares Market value As of
FSEG 0.03% 120 $ 1,594.80 Jun 30, 2026
TMSL 0.02% 40,640 $ 540.106K Jun 30, 2026
RESM 0.01% 22 $ 292.38 Jun 30, 2026
AVSC 0.00% 7,963 $ 56.537K Nov 16, 2026